Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Trivalent influenza subunit vaccine Influvac · 4 trials · 2 indications
Seroprotection and Seroconversion Rate for A/H1N1, A/H3N2, and B Strains 3 weeks After Vaccination in non-elderly adults and elderly adults.
Standard parameters to quantify antibody levels. Recommended in the CHMP guideline.
Reactogenicity and inconvenience
Other adverse events
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Trivalent influenza subunit vaccine Influvac. "3x 15mcg Hemagglutinin Antigen (HA) per 0.5 ml,trivalent one injection at Day 1 " |
| Trivalent influenza subunit vaccine Influvac | EXPERIMENTAL | 3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1 |
| Name | Type | Description |
|---|---|---|
| Trivalent influenza subunit vaccine Influvac | BIOLOGICAL | "3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1 " |
Inclusion Criteria: * Willing and able to give informed consent and able to adhere to all protocol required study procedures. * Men and women aged ≥ 18 and ≤ 60 years or ≥ 61 years of age at the day of study vaccination. * Being in good health as judged by medical history, physical examination (if ...
Trivalent influenza subunit vaccine Influvac is used for the prophylaxis of influenza, a seasonal viral infection. It is an inactivated subunit vaccine designed to protect against three influenza virus strains. The vaccine is intended for adults aged 18 years and older, as studied in clinical trials.
Trivalent influenza subunit vaccine Influvac is developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker ABT. The vaccine is being investigated for the prevention of influenza and has undergone clinical trials in multiple countries.
Trivalent influenza subunit vaccine Influvac is in Phase 3 clinical development. It is an investigational vaccine for the prophylaxis of influenza. All completed trials have been Phase 3 studies, and the vaccine is not yet approved for use.
Trivalent influenza subunit vaccine Influvac has been studied in several completed Phase 3 trials, including NCT00881842, NCT01146015, NCT01633749, and NCT02381418. These trials evaluated the vaccine's immunogenicity and safety against seasonal influenza strains in healthy adults aged 18 years and older.
Trivalent influenza subunit vaccine Influvac is commonly referred to as Influvac. The drug name includes the brand identifier Influvac, and it is a trivalent formulation containing three influenza virus strains. It is an inactivated subunit vaccine for influenza prophylaxis.